These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 4614096)

  • 21. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 23. [Combination of L-dopa and sulpiride in the treatment of Parkinson's disease].
    Brion S; Guérin R
    Cah Med; 1973 Jul; 14(8):695-8. PubMed ID: 4602472
    [No Abstract]   [Full Text] [Related]  

  • 24. [L-tryptophan therapy of DOPA psychoses].
    Birkmayer W; Neumayer E
    Nervenarzt; 1972 Feb; 43(2):76-8. PubMed ID: 4501978
    [No Abstract]   [Full Text] [Related]  

  • 25. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
    Constantinidis J; de Ajuriaguerra J
    Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of Parkinson's syndrome using L-dopa. 2].
    Glabb J; Hübner W; Glabb S
    Z Arztl Fortbild (Jena); 1973 Aug; 67(15):745-53. PubMed ID: 4594383
    [No Abstract]   [Full Text] [Related]  

  • 28. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 29. [Type II Charcot-Marie-Tooth and dopa-sensitive Parkinson disease].
    Tranchant C; Ruh D; Warter JM
    Rev Neurol (Paris); 1994; 150(1):72-4. PubMed ID: 7801046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A new determination method of L-dopa in blood (author's transl)].
    Weitbrecht WU; Birg W; Metzel E; Mundinger F
    Med Klin; 1974 Mar; 69(12):500-1. PubMed ID: 4831452
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dopamine and abnormal movements].
    Rondot P; Dumas RJ
    Rev Neurol (Paris); 1972 Jul; 127(1):99-113. PubMed ID: 4272134
    [No Abstract]   [Full Text] [Related]  

  • 34. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 36. L-dopa, behavioral activation and psychopathology.
    Murphy DL
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():472-93. PubMed ID: 4627219
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral effects of l-dopa in man.
    Goodwin FK
    Semin Psychiatry; 1971 Nov; 3(4):477-92. PubMed ID: 5173049
    [No Abstract]   [Full Text] [Related]  

  • 38. [Factors which influence infavourably l-dopa treatment].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2115-6. PubMed ID: 4590071
    [No Abstract]   [Full Text] [Related]  

  • 39. [L-dopa in the treatment of the Parkinsonian syndrome].
    Apostol-Pruskauer B; Voiculescu V
    Neurol Psihiatr Neurochir; 1973; 18(6):539-49. PubMed ID: 4790486
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of parkinsonism with the drug L-DOPA].
    Stoliarova LG; Kistenev BA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):199-205. PubMed ID: 4795170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.